

An intranasal adjuvanted, recombinant influenza A/H5 vaccine primes against diverse H5N1 clades: a phase I trial

Corresponding Author: Professor Justin Ortiz

This manuscript has been previously reviewed at another journal. This document only contains information relating to versions considered at Nature Communications.

This file contains all reviewer reports in order by version, followed by all author rebuttals in order by version.

Version 0:

Reviewer comments:

Reviewer #2

(Remarks to the Author)

The authors have addressed my comments.

Reviewer #3

(Remarks to the Author)

I thank the authors for addressing my comments.

Regarding my original comment #1: I agree that without any measurable baseline titers against clade 2.1 or 1, there is no reason to assume that baseline titers against clade 2.2, clade 2.2.1, clade 2.3.4, and clade 2.3.4.4b were present. I was only commenting that the denominator for calculating %seroconversion should be 8 for each group, instead of 7,7,3, or 0, which includes only those with clade 2.2, 2.2.1, 2.3.4, or 2.3.4.4b measured.

Open Access This Peer Review File is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

In cases where reviewers are anonymous, credit should be given to 'Anonymous Referee' and the source.

The images or other third party material in this Peer Review File are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>

REVIEWERS' COMMENTS

Reviewer #2 (Remarks to the Author):

The authors have addressed my comments.

Reviewer #3 (Remarks to the Author):

I thank the authors for addressing my comments.

Regarding my original comment #1: I agree that without any measurable baseline titers against clade 2.1 or 1, there is no reason to assume that baseline titers against clade 2.2, clade 2.2.1, clade 2.3.4, and clade 2.3.4.4b were present. I was only commenting that the denominator for calculating %seroconversion should be 8 for each group, instead of 7,7,3, or 0, which includes only those with clade 2.2, 2.2.1, 2.3.4, or 2.3.4.4b measured.

AUTHOR RESPONSE: WE HAVE REVISED THE MANUSCRIPT AND SUPPLEMENTAL TABLES THAT DESCRIBE SEROPROTECTION AGAINST CLADE 2.2, CLADE 2.2.1, CLADE 2.3.4, AND CLADE 2.3.4.4B PER THE PEER-REVIEWER SUGGESTION.